Genestack Joins the Milner Therapeutics Institute
Genestack supports members of the Milner Therapeutics Institute deliver an ecosystem approach for drug discovery.
Oct 27. 2017
Genestack supports members of the Milner Therapeutics Institute deliver an ecosystem approach for drug discovery.
It is now possible for non-bioinformaticians to create knowledge-networks – a powerful way for biologists to visualise deep connections between genes and phenotypes – quickly and efficiently thanks to the integration of Rothamsted Research’s open-source KnetMiner software into the Genestack platform.
"Cambridge business big guns have given a largely warm reception to the launch of the Government's new life sciences strategy which aims to make Britain a world leader in the sector."
Genestack has been listed as one of the Key Companies to watch in the recent Frost & Sullivan report on the Growth Opportunities in the European Next-generation Sequencing Informatics Market, Forecast to 2021.
Many key scientists lack essential skills in bioinformatics and this is potentially a bottleneck for therapeutic research in big pharma. Dr Misha Kapushesky, CEO of Genestack, will discuss how increasing pressure on bioinformaticians is slowing the pace of discovery in a webinar ‘Next-generation Sequencing: New Business Models in Diagnostics and Drug Development’ organised by Frost & Sullivan on 9th August.